Amiodarone use and all-cause mortality in patients with a continuous-flow left ventricular assist device

Authors

Rakesh Gopinathannair, Kansas City Heart Rhythm Institute Overland Park KS.
Naga Venkata Pothineni, Kansas City Heart Rhythm Institute Overland Park KS.
Jaimin R. Trivedi, Department of Cardiothoracic Surgery University of Louisville Louisville KY.
Henri Roukoz, Division of Cardiology University of Minnesota Minneapolis MN.
Jennifer Cowger, Division of Cardiology Henry Ford Hospital Detroit MI.Follow
Mustafa M. Ahmed, Division of Cardiology University of Florida Gainesville FL.Follow
Adarsh Bhan, Advocate Aurora HealthFollow
Ashwin K Ravichandran, St. Vincent Heart Center Indianapolis IN.
Geetha Bhat, Division of Cardiology Pennsylvania State University Hershey PA.Follow
Amin Al Ahmad, Texas Cardiac Arrhythmia Institute Austin TX.Follow
Andrea Natale, Texas Cardiac Arrhythmia Institute Austin TX.
Luigi Di Biase, Division of Cardiology Montefiore Medical Center New York NY.Follow
Mark S. Slaughter, Department of Cardiothoracic Surgery University of Louisville Louisville KY.
Dhanunjaya Lakkireddy, Kansas City Heart Rhythm Institute Overland Park KS.

Recommended Citation

Gopinathannair R, Pothineni NVK, Trivedi JR, et al. Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device. J Am Heart Assoc. 2022;11(11):e023762. doi:10.1161/JAHA.121.023762

Affiliations

Advocate Christ Medical Center

Abstract

Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous-flow left ventricular assist device (CF-LVAD) recipients. The purpose of this study was to assess the impact of amiodarone use on long-term all-cause mortality in ptients with a CF-LVAD. Methods and Results A retrospective multicenter study of CF-LVAD was conducted at 5 centers including all CF-LVAD implants from 2007 to 2015. Patients were stratified based on pre-CF-LVAD implant amiodarone use. Additional use of amiodarone after CF-LVAD implantation was also evaluated. Primary outcome was all-cause mortality during long-term follow-up. Kaplan-Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF-LVAD (aged 58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF-LVAD implant, and 310 (64.6%) were not on amiodarone. Rate of all-cause mortality over the follow-up period was 32.9% in the amiodarone group compared with 29.6% in those not on amiodarone (=0.008). Similar results were noted in the propensity-matched group (log-rank, =0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently associated with all-cause mortality (hazard ratio, 1.68 [95% CI, 1.1-2.5]; =0.01). Conclusions Amiodarone use was associated with significantly increased rates of all-cause mortality in CF-LVAD recipients. Earlier interventions for arrhythmias to avoid long-term amiodarone exposure may improve long-term outcomes in CF-LVAD recipients and needs further study.

Document Type

Article

PubMed ID

35656998